Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial
Simiso Mandisa Sokhela, Ernest Asante‐Appiah, Johannes Richard Bogner, Federico Hinestrosa et al.
Citations
4 citations
Journal
Clinical Infectious Diseases
Topics
HIV Research and Treatment
Field-Weighted Citation Impact (FWCI)
4.15
article
Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial
Simiso Mandisa Sokhela, Ernest Asante‐Appiah, Johannes Richard Bogner, Federico Hinestrosa, Hiroyuki Gatanaga, Jade Ghosn, Douglas Cunningham, Jean‐Michel Molina, Karen Eves, Todd Correll, Stephanie O. Klopfer, Jürgen Kurt Rockstroh, Pedro Cahn, Michelle C. Fox, Mary L. Pisculli, Roger Paredes, Ying Zhang, Kathleen Squires, Sheetal Kassim, Uchechukwu Nwoke
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
Clinical Infectious DiseasesVol. 81(2)
Institutions
Université Claude Bernard Lyon 1 (FR), Délégation Paris 5 (FR), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Desmond Tutu HIV Foundation (ZA), Inserm (FR), University of the Witwatersrand (ZA), Université Paris Cité (FR), University Hospital Bonn (DE), Hospital Universitario La Paz (ES), LMU Klinikum (DE), IrsiCaixa (ES), Sorbonne Paris Cité (FR), National Center for Global Health and Medicine (JP), Assistance Publique – Hôpitaux de Paris (FR), Fundación Huésped (AR), Hôpital Lariboisière (FR), Orlando Immunology Center (US), Health Foundation (GB), Hôpital Bichat-Claude-Bernard (FR), Hospital Universitari Germans Trias i Pujol (ES), Case Western Reserve University (US), Ludwig-Maximilians-Universität München (DE)